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Abstract
Background: It has become increasingly apparent that the trophectoderm (TE) at blastocyst stage is much more
mosaic than has been appreciated. Whether preimplantation genetic screening (PGS), utilizing a single TE biopsy
(TEB), can reliably determine embryo ploidy has, therefore, increasingly been questioned in parallel.
Methods: We for that reason here established 2 mathematical models to assess probabilities of false-negative and
false-positive results of an on average 6-cell biopsy from an approximately 300-cell TE. This study was a
collaborative effort between investigators at The Center for Human Reproduction in New York City and the Center
for Studies in Physics and Biology and the Brivanlou Laboratory of Stem Cell Biology and Molecular Embryology,
the latter two both at Rockefeller University in New York City.
Results: Both models revealed that even under best case scenario, assuming even distribution of mosaicism in TE
(since mosaicism is usually clonal, a highly unlikely scenario), a biopsy of at least 27 TE cells would be required to
reach minimal diagnostic predictability from a single TEB.
Conclusions: As currently performed, a single TEB is, therefore, mathematically incapable of reliably determining
whether an embryo can be transferred or should be discarded. Since a single TEB, as currently performed,
apparently is not representative of the complete TE, this study, thus, raises additional concern about the clinical
utilization of PGS.
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Background
It is still widely presumed that elimination of aneuploid
embryos prior to embryo transfer improves implantation
and clinical pregnancy rates, and reduces spontaneous
miscarriages. Preimplantation genetic screening (PGS) is,
therefore, clinically still widely utilized [1, 2], though so
far has failed to produce expected outcome improvements
[3, 4]. Individual studies and meta-analyses, indeed,
suggested that the procedure may affect IVF outcomes
adversely [5–9]. Challenging the biological concept of
PGS, questions also arose whether a single trophectoderm
(TE) biopsy (TEB), indeed, can reliably reflect ploidy of
the total TE, how accurately a TE biopsy represents the
inner cell mass (ICM), from which the embryo arises, and
how extensively an embryo self-corrects downstream from
blastocyst stage [10, 11].
That embryos self-correct to highly significant degrees
was strongly suggested in a recent mouse study, when
early stage embryos, even when highly chimeric for
euploid and aneuploid cell lineages, remarkably self-
corrected downstream from blastocyst stage. Moreover,
self-correction was more efficient within the ICM than
within TE, from which the placenta develops (Fig. 1)
[12]. Faced with such genetic heterogeneity between
early embryonic compartments, more aneuploid cells
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would, therefore, be expected in TE than ICM. Yet, in the
current utilization of PGS (PGS 2.0), embryo biopsies are
exclusively obtained from the TE.
Until very recently, any detectable aneuploidy in a
single TEB was labeled as abnormal (aneuploid), and re-
sulted in disposal of so-affected embryos. Recent studies,
however, suggested that such an approach results in
large numbers of false-positive diagnoses, exclusion of
patients from access to embryo transfers, and disposal of
normal (euploid) embryos [10, 11] with potential for
normal euploid births [11, 13, 14]. A recent Position State-
ment on PGS from the Preimplantation Genetic Inter-
national Society (PGDIS), therefore, defined radically new
diagnostic criteria for PGS (Tables 1, 2 and 3) [15].
The PGDIS, thus, acknowledged that prior reporting
schemes over-diagnosed aneuploidy. Especially patients
with small embryo numbers will be negatively affected by
such false-positive diagnoses [2–4, 6]. The society also ac-
knowledged that not only euploid but also selected mosaic
embryos now may be transferred, and that a single TEB,
therefore, likely is unable to accurately determine whether
an embryo is euploid, mosaic-benign or aneuploid.
If a single TEB is unable to offer an accurate diag-
nosis that allows determination of the ploidy status
of the embryo with certainty, the clinical purpose for
the utilization of PGS in IVF becomes unclear. This
Fig. 1 Schematics of PGS. The currently in use PGS procedure (PGS 2.0) is based on a single TEB of on average approximately 6 cells, which is
alleged to accurately reflect the chromosomal status of the developing embryo/fetus. The procedure has entered worldwide clinical use without
prior clinical validation. Three crucial questions (unresolved issues in the figure) still require resolution. This manuscript attempts to answer the
first of these questions, whether a single TEB accurately enough reflects the whole TE to discriminate between embryos that can undergo
transfer and those that should be discarded
Table 1 PGDIS Recommendations for PGS laboratories [15]
1. For reliable detection of mosaicism, ideally 5 cells should be biopsied,
with as little cell damage as possible. If the biopsy is facilitated using
a laser, the identified contact points should be minimal and
preferably at cell junctions. Overly aggressive use of the laser may
result in cell damage and partial destruction of cellular DNA.
2. Only a validated Next Generation Sequencing (NGS) platform that
can quantitatively measure copy numbers should be used for
measurement of mosaicism in the biopsy sample. Ideally, a NGS
methodology that can accurately and reproducibly measure 20%
mosaicism in a known sample.
3. For reporting embryo results, the suggested cut-off point for
definition of mosaicism is >20%, so lower levels should be treated
as normal (euploid), > 80% abnormal (aneuploid), and the remaining
ones between 20 and 80% mosaic (euploid-aneuploid mosaics).
Table 2 PGDIS recommendations for the clinician [15]
1. Patients should continue to be advised that any genetic test
based on sampling one or small number of cells biopsied from
preimplantation embryos cannot be 100% accurate for a combination
of technical and biological factors, including chromosome mosaicism.
2. The patient information and consent forms for aneuploidy testing
(if used) should be modified to include the possibility of mosaic
aneuploid results and any potential risks in the event of transfer
and implantation. This needs to be explained to patients by the
clinician recommending the aneuploidy testing.
3. Transfer of blastocysts with a normal euploid result should always
be prioritized over those with mosaic aneuploid results.
4. In the event of considering the transfer of a blastocyst with only
mosaic aneuploidies, the following options should be discussed
with the patient:
a. A further cycle of IVF with aneuploidy testing to increase the
chance of identifying a normal euploid blastocyst for transfer
b. Transfer of a blastocyst with mosaic aneuploidies for low risk
chromosomes only, after appropriate genetic counseling if available
c. Appropriate monitoring and prenatal diagnosis of any resulting
pregnancy, preferably by early amniocentesis (14 weeks gestation).
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study, therefore, explored with mathematical model-
ing the most basic question of PGS, −whether a
single random TEB can define the expected preva-
lence of more than one cell clone/lineage in TE of
blastocyst-stage embryos.
Since PGS depends on a single TEB, the prevalence
of TE mosaicism and/or outright aneuploidy in a sin-
gle TEB is key to the potential clinical utility of such
a biopsy. If frequency of mosaicism makes it impos-
sible for a single biopsy to be representative of total
TE, PGS would be invalidated, without even having
to consider how well TE reflects the ICM or how
much such a biopsy reflects final embryo fate in view
of the embryo’s innate ability to self-correct down-
stream from blastocyst stage.
Methods and results
The probability of a false negative diagnosis when biopsy
shows no mosaicism
A tempting conclusion from observing only euploid
cells in a biopsy is that the whole embryo is euploid.
However, there is also the risk of, by chance, not hav-
ing picked any aneuploid cells in the biopsy, even
though some were present. This risk of this happen-
ing depends on the number of aneuploid cells in the
embryo. We here determine the probability that a
biopsy shows no mosaicism as a function of the
fraction of euploid cells r = N1=N , where N1 is the
number of euploid cells, and N the total number of
cells.
Assuming that the cells are drawn at random from
the trophectoderm, the probability of observing k eu-
ploid cells in an n-cell biopsy is given by the hypergeo-








The probability of not observing any aneuploid cells in
the biopsy although there are some present (i.e. r < 1),
is given by observing only euploid cells (k = n) which
gives







and which is plotted for different ratios r in Fig. 2 for n = 6
(6 cells per TEB) and N = 300 (300 cells per average TE at
blastocyst stage).
We note that there is a high probability of not observ-
ing mosaicism in the biopsy even when the ratio of
euploid cells is relatively low. In particular, even a quite
mosaic embryo with only 60% euploid cells leads to
observing no mosaicism in the biopsy in more than 5%
of the cases. In more technical terms, equation (1) is the
P-value for the hypothesis that the ratio of euploid cells
is r. It shows that any value of r larger than 60% euploid
cells leads to a P-value that is larger than the usual
significance level of 5% (indicated as a dashed line in the
figure), meaning that even the hypothesis that there are
40% aneuploid cells in the embryo cannot be rejected
when not observing any aneuploid cells in the biopsy.
One can also ask the reverse question; i.e. how large
would the biopsy need to be so that one can be
confident that the embryo consists of at least a certain
high fraction of euploid cells. We can calculate the size
Table 3 PGDIS guidelines to prioritize mosaic embryos for
transfer [15]
Based on our current knowledge of the reproductive outcomes of fetal
and placental mosaicism from prenatal diagnosis, the following can be
used as a guide by the clinician (or a genetic counselor if available)
when a mosaic embryo is being considered for transfer:
1. Embryos showing mosaic euploid/monosomy or mosaic euploid/
monosomy are preferable to euploid/trisomy, given that monosomic
embryos (excepting 45, X) are not viable
2. If a decision is made to transfer mosaic embryos trisomic for a
single chromosome, one can prioritize selection based on the
level of mosaicism and the specific chromosome involved
a. The preferable transfer category consists of mosaic embryos
trisomic for chromosomes 1, 3, 4, 5, 6, 8, 9, 10, 11, 12, 17, 19,
20, 22, X, Y. None of these chromosomes involve the adverse
characteristics enumerated belowb.
b. Embryos mosaic for trisomies that are associated with potential
for uniparental disomy are of lesser priority
c. Embryos mosaic for trisomies that are associated with intrauterine
growth retardation (chromosomes 2, 7, 16) are of lesser priority.
d. Embryos mosaic for trisomies capable of liveborn viability
(chromosomes 13, 18, 21) are for obvious reasons of lowest
priority
Fig. 2 P-values for observing no mosaicism, given different
hypotheses r and a threshold of 0,05 (dotted line). With the curve
crossing the significance line (P = 0.05) at 0.6, the figure demonstrates
that any value of r larger than 60% euploid cells leads to a P-value that
is larger than the usual significance level of 5% (indicated as a dashed
line in the figure), meaning that even the hypothesis that there are
40% aneuploid cells in the embryo cannot be rejected when not
observing any aneuploid cells in the biopsy
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of the biopsy for which it would very likely (>95%) not
be all-euploid, by equating expression (1) with 0.05 and
by then solving for the biopsy size n. For example, one
would need a biopsy of 27 cells to assure that the prob-
ability of obtaining only euploid cells in a biopsy is less
than 5% if the fraction of euploid cells in the embryo
is r = 0.9 (i.e. for a biopsy size of n = 27, only hypoth-
eses r > 0.9 are compatible with an all-euploid biopsy,
and in 95% of the cases one would observe a mosaic
biopsy).
The probability of false positive diagnosis when biopsy
shows mosaicism
We now calculate the probability that the embryo is,
to a significant degree, normal-euploid and non-
mosaic (i.e., can have a large r), even though the bi-
opsy includes one or more aneuploid cells. Similar to
the above calculation, we are interested in the largest
r that is still compatible with a biopsy that includes
aneuploid cells. We analyze the case of different
numbers of aneuploid cells in the biopsy separately.
The most extreme (i.e. unlikely case, assuming that
there is a dominating constitutional lineage) is that all
6 cells are abnormal-aneuploid, which is given by the
hypergeometric distribution with k = 0 (no euploid
cells), leading to







This gives us the P-value or probability that, for a
given ratio of euploid cells in the embryo, r, 6
aneuploid cells are observed. If there are 5 abnormal-
aneuploid cells, the P-value is calculated by adding up
the probability of getting 5 abnormal cells and the
more extreme case of 6 abnormal cells, and so on for
the other cases, leading to a P-value pi (indicating a
biopsy with i abnormal cells) of
pi ¼
Xn
j¼ih n−j; n;N1;Nð Þ ð3Þ
The P-values for different biopsies outcomes and
hypotheses is, therefore, plotted in Fig. 3. The figure
allows easy determination of the largest r that cannot be
rejected (i.e. where the lines cross the significance level).
As already explained above, in determining the inter-
pretation of a TEB negative for aneuploid cells, the
curves in Fig. 3 demonstrate that, even when obtaining a
mosaic TEB, with decreasing aneuploidy cell numbers in
the TEB (from 6 to 1), any explanation with increasing r
from r < 0.4 to r < 0.99 could be a reasonable explanation
of the observed data since it leads to observing mosai-
cism in >5% of cases. The threshold at which r crosses
the significance level increases with decreasing aneu-
ploidy. This means that a given r is more likely to
explain the obtained biopsy result the lower the mea-
sured aneuploidy is. For example, if one (or more) cells
are aneuploid, the threshold will be approximately r =
0.99, meaning that even a hypothesis of r = 0.99, basically
an entirely euploid embryo, is compatible with the data.
On the other hand, if three (or more) cells are aneuploid,
a hypothesis with an r as high 0.99 is too unlikely to give
the observed data, and only an r < 0.85 hypothesis is
compatible with this biopsy outcome.
Fig. 3 P-values for observed mosaicism, given different hypotheses r, and varying numbers of abnormal-aneuploid cells in biopsy. The curves
demonstrate that, even when obtaining a mosaic TEB, with decreasing aneuploidy cell numbers in the TEB (from 6 to 1), any explanation with
increasing r from r < 0.4 to r < 0.99 could be a reasonable explanation of the observed data since it leads to observing mosaicism in >5% of
cases. The threshold at which r crosses the significance level increases with decreasing aneuploidy. This means that a given r is more likely to
explain the obtained biopsy result the lower the measured aneuploidy is. For example, if one (or more) cells are aneuploid, the threshold will be
approximately r = 0.99, meaning that even a hypothesis of r = 0.99, basically an entirely euploid embryo, is compatible with the data. On the other
hand, if three (or more) cells are aneuploid, a hypothesis with an r as high 0.99 is too unlikely to give the observed data, and only an r < 0.85
hypothesis is compatible with this biopsy outcome
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What models for false-negative and false-positive diagno-
ses, therefore, demonstrate is that, in both instances, the
uncertainty about accuracy is so high that a single TEB of-
fers limited clinical value for determining prevalence and
degree of TE aneuploidy. And this uncertainty does not
even yet relate to the uncertainty about how TE aneuploidy
relates to ICM aneuploidy and, finally, to the apparently
remarkable ability of the ICM to self-correct, even if at
blastocyst stage still highly chimeric between a constitu-
tional euploid and non-constitutional aneuploidy cells
(Fig. 1 and [12]).
Two additional points are of importance: Here pre-
sented models are best case scenarios because they
assume an even distribution of non-constitutional cell
lines throughout the TE, which in itself is unlikely. More
likely is a clonal insular distribution akin to aneuploid
cell island described in the placenta [16], which arises
from the TE. Such a distribution would, however, further
lower here already inadequately low predictive abilities
of a single TEB. In addition, both here presented models
clearly demonstrate that even the new PGDIS criteria to
define embryos as normal, mosaic and aneuploid based
on percentages of aneuploidy (Table 1), are unsustainable
because they do not permit the one decision why PGS 2.0
is performed by clinicians, − to determine whether em-
bryos can be transferred or should be discarded. As our
second model (Fig. 3) demonstrates, even 80% aneuploidy
in a single TEB is compatible with the hypothesis of an
embryo being approximately 60% euploid. Even a level of
80% aneuploidy in a single TEB, therefore, cannot be used
as a convincing rational to discard so assessed embryos.
One, therefore, has to wonder what the remaining clinical
purpose of PGS 2.0 might be?
Discussion
Embryos with any chromosomal abnormality were until
recently routinely discarded before publication of the
new PGDIS criteria [15]. Figure 3 demonstrates that,
based on the ratio of euploid/aneuploidy cells in a TEB,
different degrees of mosaicism can be considered rea-
sonable explanations of the data, with declining numbers
aneuploid cells in the TEB decreasing the likelihood that
a given ratio of euploid/aneuploid cells can explain the
data observed.
Decreasing aneuploidy increases the P-value for a
given r, and also increases the threshold r, for which the
r < r threshold is a valid explanation for the biopsy data.
Since a very high r means almost no mosaicism, decreas-
ing numbers of aneuploid cells in the TEB lead to the
hypothesis that an increasingly non-mosaic euploid em-
bryo has to be considered a reasonable explanation for
the observed biopsy results.
Here presented models assume that a single TEB on
average involves 6 TE cells, and that a healthy blastocyst
stage embryo demonstrates a TE of approximately 300
TE cells. The latter number is based on a recently
published human in vitro implantation model [17] and
differs from TE cell numbers reported in earlier studies
obtained in embryos from preimplantation-stage blasto-
cysts, which suggested a smaller TE cell pool of ca.70-120
cells [18, 19].
Even assuming the TE cell pool to be smaller than 300
cells, magnitude of here reported mathematical uncer-
tainty beyond reasonable doubt demonstrates that a
single TEB cannot reflect the total TE. Even under the
unrealistic assumption of even distribution of mosaicism,
it would take at least a 27-cell biopsy to reach a minimal
level of correct statistical representation. A 6-cell biopsy
is, therefore, never accurate enough to decide whether
an embryo should be discarded or not.
Here presented mathematical models also offer a likely
explanation why reported live birth rates after transfer of
allegedly aneuploid/mosaic embryos have been surpris-
ingly high [11, 13, 14], and why these results contradict
newly published PGDIS criteria, attempting to redefine
clinically relevant degrees of embryo mosaicism (i.e., “eu-
ploid-normal” <20% aneuploidy, “euploid-aneuploid mo-
saic” at ≥20–80%, and “abnormal-aneuploid” at >80%)
([15] and Table 1). The PGDIS also defines a TEB by only
5-cells, thereby further reducing the potential predictabil-
ity of a single biopsy, and more than compensating should
the assumption of 300 TE cells in our models have been
too high [18, 19]. A 5-cell TEB also means that 1 to 4 an-
euploid cells in a single TEB define an embryo as mosaic.
As this new PGDIS guideline also sets <20% aneuploidy
for the definition of euploid-normal (Table 1), an embryo
under this new definition, therefore, would be “normal”
only if a single TEB contains zero aneuploid cells.
The PGDIS’ new definitions of euploid-normal, mosaic
and aneuploidy-abnormal, therefore, defy logic on theoret-
ical as well as practical grounds. They also offer a good
example why genetic test validations should not be based
on technical limits of diagnostic platforms but on appro-
priate clinical validation studies before such platforms are
introduced into routine clinical practice.
How mosaic TE is, how many individual cell clones are
spread throughout the TE, how expansive each clone is
and how individual clones are distributed among TE cells
(sticky-clustered or evenly distributed) is, of course, essen-
tial to any understanding of how well (or poorly) a single
TEB represents the whole TE. Not one of these defining
factors of mosaicism is, however, currently known.
Munné’s group recently demonstrated how limited
current knowledge is [20]: Utilizing array comparative gen-
omic hybridization (CGH) and next generation sequencing
(NGS), they analyzed the age-prevalence of chromosomal
abnormalities. Among large numbers of investigated em-
bryos, CGH (which cannot differentiate between aneuploid
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and mosaic embryos) at all ages defined more embryos as
aneuploid than NGS, which is claimed to differentiate
between euploid, mosaic and aneuploid embryos based on
percentages of aneuploidy ([15] and Table 1).
Adding, however, up aneuploid and mosaic findings
after NGS, we noted that NGS at all ages detected signifi-
cantly more non-euploid embryos than CGH. Though
aneuploid embryos increased with advancing age with
both platforms, the study’s authors noted that mosaicism
in infertile women, actually, significantly decreased with
advancing age. Incompatible with this finding, and unex-
plained by the authors, egg donors, however, paradoxically
demonstrates almost as low mosaicism rates as oldest
women (>40 years) [20].
How a single random TEB, involving ca. 6 cells
[15, 21] in a ca. 300 cell T [17], reflects the overall
chromosomal heterogeneity of the total TE, was,
until here reported mathematical models were ap-
plied, unknown. PGS 2.0 was, nevertheless, clinically
initiated without proper prior validation studies. This
is especially noteworthy since a main argument for
advancing from PGS 1.0 (utilizing blastomere biopsy
at cleavage stage) to PGS 2.0 (TEB at blastocyst
stage) was allegedly reduced mosaicism [22].
Recently evolving data suggest the opposite: Like can-
cer cells, blastomeres of early stage human embryos
exhibit increased expression of gene products involved
in cell cycle progression, while apparently lacking
expression of cell cycle checkpoint genes. Convergence
of these two properties at blastocyst stage, due to in-
creased mitotic error rates [23], may at least in part ex-
plain increased genetic instability and increasing TE
mosaicism. Stress imposed by extended embryo culture
may also contribute to increased mosaicism [24]. PGS
1.0 years ago was declared ineffective in improving IVF
outcomes [25–28]. As here presented models suggest,
PGS 2.0 appears on the way to meet a similar fate,.
Reports on the prevalence of TE mosaicism at blasto-
cyst stage have not been consistent: An Italian group re-
ported between 3 to 8% [14, 29]. As noted, Munné’s
group reported that TE mosaicism declined with advan-
cing age (from 22.66% <35 years to 9.70% >42). Paradoxic-
ally, young egg donors, however, behaved like oldest
women by demonstrating mosaicism in only 11.35% [20].
Adding up euploid and mosaic embryos, percentages,
however, suddenly make age-specific sense, with young
egg donors demonstrating lowest aneuploidy/mosaicism
rates (26.06%), gradually increasing to 79.54% in oldest
infertile women above age 42.
Most so far published PGS studies in the literature
have not defined mosaicism in accordance with recently
issued PGDIS guidelines, nor did they use, as suggested,
NGS platforms (Table 1). They, therefore, can no longer
be considered authoritative. The new PGDIS criteria,
however, are also still insufficient since they are based
on alleged sensitivities of selected NGS platforms to
detect mosaicism quantitatively. Yet, they lack any
clinical validation studies.
For the third time in the history of PGS, the PGS la-
boratory community, therefore, without prior clinical
validation studies, has chosen to establish completely
arbitrary diagnostic criteria to differentiate between
euploid (<20% aneuploidy), mosaic (20–80% aneu-
ploidy) and aneuploid embryos (>80% aneuploidy [15],
claiming that such differentiation can be the basis for
clinical decisions on whether to transfer or dispose of
any given embryo. We here demonstrate the futility of
this claim.
TE mosaicism significantly exceeds previously reported
rates: Less than 20% of embryos were identically
assessed on multiple biopsies in different PGS laborator-
ies [11]. Over a-third of embryos initially reported as
aneuploid, on repeat biopsy were found to be euploid-
normal [11]. Evaluating multiple TEB biopsies from
same embryos in same PGS laboratories, only approxi-
mately 50% of biopsies were congruent [11]. TE mosai-
cism, mosaicism, therefore, exists in, likely, at least 50%
of embryos and with considerable certainty in close to
100%. Congruence between multiple TEBs and ICM
biopsies was also poor [10], offering additional evidence
that a single TEB cannot reliably determine the chromo-
somal status of a blastocyst stage embryo. As noted
before, based on increasing chromosomal instability with
extended embryo culture [23, 24], TE mosaicism may
actually reflect a normal physiological stage in embryo
development in preparation for implantation. Munné’s
group’s suggestion that mosaicism declines with advan-
cing maternal age [20], could then, at least partially,
explain declining implantation rates in older women.
Conclusions
The primary goal of this communication was defining
the likelihood of TE mosaicism in human blastocyst-
stage embryos. The primary question of interest was,
however, how accurately can a single TEB reflect the
ultimate chromosomal fate of an embryo? The answer
depends on five distinct components: (i) How accurate is
the diagnostic platform in determining whether a speci-
men is euploid, mosaic or aneuploid? (ii) How accurately
does this one TEB, involving approximately 6 cells,
reflect the total TE? (iii) How well does this one TEB
reflect ploidy of the ICM? (iv) What is the age of the
mother? (v) How well does the ICM, ultimately self-
correct downstream from blastocyst stage?
Results of embryo biopsies can significantly vary be-
tween diagnostic platforms [30]. The recent PGDIS
statement extensively refers to the use of appropriate
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platforms ([15] and Table 1). Yet, surprisingly, none has
so far been vetted by the U.S. Food and Drug Adminis-
tration (FDA), and even formal comparisons between
marketed systems are lacking.
We here confirmed that TE mosaicism must be more
common at blastocyst stage than has been initially sug-
gested by proponents of PGS 2.0 [22]. Though our
models cannot offer specific probabilities, here presented
data strongly suggest that a single TEB cannot accurately
enough determine whether, and to what degree, a given
embryo is mosaic and/or aneuploid. A single TEB, there-
fore, is not sufficient to determine whether an embryo
can be transferred or should be discarded, rendering
PGS 2.0 as a clinical tool ineffective.
How this variability of outcome with a single TEB
relates to the ICM is unknown. After dividing embryos
into four specimens, Munné’s group recently reported
that mosaicism was confined to only TE or ICM in 39%
of embryos. In 25% of embryos, the ICM was mosaic,
yet, one or two TE biopsies were euploid [29]. Their
study, thus, confirms relative poor correlations between
TE and ICM, a findings first suggested by Orvieto et al.
[10]. This observation, of course, further reduces the
relevance of a single TEB in defining embryo ploidy.
Aneuploid cell lineages increase with advancing female
age [20], likely increasing the ratio of non-constitutional to
constitutional cells and, thereby, further reducing the ac-
curacy of a single TE biopsy. When in older women, accur-
ate diagnosis of ploidy is needed most, PGS 2.0, therefore,
appears least accurate. Considering that embryo numbers
decline with advancing age, it, therefore, should not
surprise that PGS, even in its earlier format (PGS 1.0)
already was demonstrated to adversely affect IVF outcomes
in older women and poorer prognosis patients [6, 8].
The ultimate question to be answered is, however,
how well the ICM, from which the fetus arises, self-
corrects downstream from blastocyst stage? If human
embryos have a similar ability of self-correction as mice
[12], a TEB at blastocyst stage would seem non-sensical.
Even, assuming the unlikely ability to biopsy the ICM
rather than the TE of blastocyst-stage embryos, results
would mean little since the evolving embryo would still
have significant capacity to self-correct downstream.
We, therefore, conclude that the basic biology of early
embryonic development invalidates the concept of PGS.
It, therefore, should not surprise that PGS 1.0 failed and,
ultimately, was declared ineffective [24–27], and that
increasing clinical data now also suggest ineffectiveness
of PGS 2.0.
Recently published national U.S. data from the Centers
for Disease Control and Prevention (CDC), comparing
outcomes in IVF cycles with and without PGS, suggested
potential negative effects from PGS [31]. Analyses of
national Society for Assisted Reproduction (SART) data,
further strengthened those conclusions by also demon-
strating negative outcome effects from PGS, even in best
prognosis patients (Barad DH, Darmon S, Kushnir VA,
Lazzaroni-Tealdi E, Wang Q, Zhang L, Albertini DF,
Gleicher N. Detrimental effects of preimplantation gen-
etic screening (PGS) on 2005-2013 oocyte recipient cy-
cles, In revisions). That prospective studies of PGS were
unable to demonstrate outcome benefits from PGS,
whether in its first (PGS 1.0) or its current format (PGS.
2.0) [3, 4], should, therefore, not surprise.
Increasing numbers of healthy offspring delivered
following transfers of allegedly aneuploid/mosaic em-
bryos [11, 13, 14] have called further into doubt the
longstanding policy of discarding such embryos. This
was recognized by the PGDIS ([15] and Tables 2 and 3),
the first formal acknowledgement that, until recently,
large numbers of embryos with euploid live birth poten-
tial have been mistakenly disposed all around the world.
Some investigators suggested that transfer of mosaic
embryos reduces implantation rates in comparison to
transfer of euploid embryos [15, 32]. Their conclusions
have, however, be viewed with caution since studies
that have made this claim utilized diagnostic platforms
incapable of accurately discriminating between benign
embryo mosaicism and true embryo aneuploidy. There
is, indeed, considerable evidence to the contrary: That
includes rather high live birth rates from transferred
aneuploid/mosaic embryos in mostly poor prognosis
patients [11, 13, 14].
To summarize, our mathematical modeling of a single
TEB to accurately assess presence of mosaicism, demon-
strates that such a single biopsy cannot reliably evaluate
ploidy of TE and/or embryo to determine whether an
embryo should be transferred or discarded. PGS 2.0,
therefore, remains a procedure in search of a clinical
application [4], and should not be offered clinically in
attempts to improve IVF outcomes.
Finally acknowledging shortcomings of PGS 2.0, the
recent Position Statement of the PGDIS [15] still falls
short, as it does not offer the option of reducing the use
of PGS in association with routine IVF. Remarkably, in-
deed, as first and preferred option in cases where PGS
2.0 only reports mosaic blastocysts in an IVF cycle, the
new recommendation is “a further cycle of IVF with
aneuploidy testing to increase the chance of identifying a
normal-euploid blastocyst for transfer” (Table 2). Our
study establishes that such a recommendation does not
rely on any scientific evidence.
Joyner et al. recently discussed in JAMA the unfor-
tunate tendency of underperforming big ideas in
research, nevertheless, to become entrenched in clin-
ical medicine [33]. In reproductive medicine, PGS in-
creasingly looks like the posterchild for an
underperforming idea.
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